CQDM Canada Belgium Program

Sponsor

CQDM

Program

Canada Europe Joint funding initiative

Description

The main goal of the Canada/Government of Wallonia/BioWin joint program is to strengthen biomedical research in Canada and Wallonia  by aligning scientific resources and expertise.   This collaborative program gives the opportunity for researchers based in Canada and Wallonia to develop new expertise and to expand into new markets.
 
This program is meant to finance the development of novel and potentially transformative next-generation technologies or tools with the potential to improve, enhance, or accelerate the drug discovery and/or development process.
 
This program is not intended to fund research on new drugs for specific therapeutic segments.
 
This program promotes creativity, innovation and collaborative efforts between academic institutions and private organizations.

Eligibility

Must include a strong collaboration between at least one research entity (academic or private) in Canada and at least one private entity in Wallonia.

Funding Availability

Maximum $750,000 EU  in Wallonia and $700,000 in Canada.

Indirect Costs

40%

Special Notes

Licensing Policy
 
  • A research agreement must be signed by all research entities involved in the project within 3 months after the funding confirmation.
  • Intellectual property generated under this funding program will be managed according to the policies of the financial partners involved.
  • A licence option will be granted to the CQDM industrial sponsors (currently Merck and Pfizer and their subsidiaries) for the use of the results for R&D purposes only.  The main conditions of the end user license option will be negotiated before the beginning of the project and will take into account pre- existing IP as well as contribution from each party. 
  • CDQM industrial sponsors will have no rights to commercialize the IP resulting from the project or the pre-existing IP.

Letter of Intent External Deadline

Candidates should submit their letter of intent before January 8th, 2016 by using the form available on the website.

 

Candidates have until February 8th, 2016 to submit their full application.

Internal Deadline:  Please submit a copy of your full application along with a signed OR5 form to the Research Services email address at resserv@uoguelph.ca by 4.30 pm on Monday, January 26, 2016.  It is not necessary to submit your letter of intent internally.

Deadlines

If College-level review is required, your College will communicate its earlier internal deadlines.

TypeDateNotes
Internal Deadline

Full Proposal: Please submit a copy of your full application along with a signed OR5 form to the Research Services email address at resserv@uoguelph.ca.  It is not necessary to submit your letter of intent internally.

External Deadline

For full proposal.

How to Apply

Please see the LOI and proposal information and forms.

Each research proposal must: 

  • Include strong collaboration between at least one research entity (public or private) in Canada and at least one private entity in Wallonia.  In Canada the participation of a private organization is highly encouraged and preferred, but not mandatory, Universities and their hospitals and research centres are eligible.
  • Generate clear deliverables with immediate applications in the drug discovery and/or development process of new therapeutics.
  • Be highly innovative with a strong and wide potential impact on biopharmaceutical research.
For Questions, please contact

Marc Thibault
Director of Programs
CQDM
514-766-6661, ext. 2190
mthibault@cqdm.org (email address)
www.cqdm.org

Office of Research

Linda McCorkindale, Contracts Officer
Office of Research Services
519-824-4120 x56257
lmccorki@uoguelph.ca

Alert Classifications
Category:
Funding Opportunities and Sponsor News

Disciplines:
Health and Life Sciences
Physical Sciences and Engineering